Fresenius Medical Care Receives Regulatory Approval for New Phosphate Binding Agent in Germany

Fresenius Medical Care ("the Company"), the world'slargest provider of Dialysis Products and Services, has receivedregulatory approval from Germany's Federal Institute for Drugs andMedical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte)for a new phosphate binding agent. The drug "OsvaRen" is expected tobe introduced to the German market in the second half of 2006. TheCompany aims at quickly receiving accelerated approval for the newphosphate binding agent in other countries within the European Unionusing the mutual recognition process. The new phosphate binding agentshould be introduced in all European Countries in 2007.

The newly approved product is a phosphate binding agent that ismade from a combination of calcium acetate and magnesium carbonate.Excess phosphate consumed with food is normally removed by the kidneysin a process that can only partially be replaced by dialysis inpatients with chronic kidney failure. Too much phosphate in the bloodcan result in mid-term damages to bones and blood vessels. The risk ofsuch damages can be lowered by regularly taking in phosphate binders.The new compound from Fresenius Medical Care combines two substancesknown to support bone health while optimizing the levels of calcium.

With the approval of the new drug Fresenius Medical Care has madea further step to develop new business opportunities with new renaltherapy options combining dialysis expertise in products and serviceswith certain drugs commonly used in dialysis.

"The expansion of our business into the renal drug arena for thetreatment of patients with chronic kidney failure is part of ourhorizontal diversification. By further strengthening our broadportfolio of dialysis-related products and therapies, we create thebasics for sustainable and profitable growth of our Company. This is avery interesting step where we are now able to partially address suchopportunities in the market place" said Dr. Emanuele Gatti, FreseniusMedical Care Management Board Member responsible for Europe, LatinAmerica, the Middle East and Africa.

Fresenius Medical Care is the world's largest, integrated providerof products and services for individuals undergoing dialysis becauseof chronic kidney failure, a condition that affects more than1,400,000 individuals worldwide. Through its network of approximately2,045 dialysis clinics in North America, Europe, Latin America,Asia-Pacific and Africa, Fresenius Medical Care provides dialysistreatment to approximately 158,700 patients around the globe.Fresenius Medical Care is also the world's leading provider ofdialysis products such as hemodialysis machines, dialyzers and relateddisposable products. Fresenius Medical Care is listed on the FrankfurtStock Exchange (FME, FME3) and the New York Stock Exchange (FMS,FMS-p).

For more information about Fresenius Medical Care visit theCompany's website at www.fmc-ag.com.

This release contains forward-looking statements that are subjectto various risks and uncertainties. Actual results could differmaterially from those described in these forward-looking statementsdue to certain factors, including changes in business, economic andcompetitive conditions, regulatory reforms, foreign exchange ratefluctuations, uncertainties in litigation or investigativeproceedings, and the availability of financing. These and other risksand uncertainties are detailed in Fresenius Medical Care AG & Co.KGaA's reports filed with the U.S. Securities and Exchange Commission.Fresenius Medical Care AG & Co. KGaA does not undertake anyresponsibility to update the forward-looking statements in thisrelease.